BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $128
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowers the price target from $142 to $128.
August 29, 2024 | 9:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BMO Capital has maintained its Market Perform rating on Neurocrine Biosciences but has lowered the price target from $142 to $128, indicating a more cautious outlook.
The lowering of the price target by BMO Capital suggests a less optimistic view on the stock's potential upside, which could lead to a negative short-term impact on NBIX's stock price. The Market Perform rating indicates a neutral stance, but the reduced price target may influence investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100